Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis

Abstract

OBJECTIVES: Given the improved efficacy of the nasal live-attenuated influenza virus vaccine (LAIV) compared with the injectable vaccine in children, we aimed to determine its safety in individuals with cystic fibrosis (CF). METHODS: A cohort of 168 study participants, aged 2 to 18 years with CF, vaccinated with LAIV between October 1, 2012, and January 30, 2013, was followed prospectively for 56 days after initial vaccination in 3 pediatric CF clinics across the province of Quebec. Days 0 to 28 post-LAIV were considered the at-risk period for all outcomes of interest, and days 29 to 56 post-LAIV were considered the non–at-risk period. Incident respiratory deteriorations were defined as an unscheduled medical visit, hospitalization, or a new course of oral antibiotics for respiratory complaints. Using a self-controlled design, incidence rate ratios (IRR) were used to compare at-risk and non–at-risk periods. RESULTS: Comparing at-risk to non–at-risk periods, there was no significant increase in the rate of incident respiratory deteriorations (IRR, 0.72; 95% confidence interval, 0.11–4.27) or all-cause hospitalizations (IRR, 1.16; 95% confidence interval, 0.30–4.81). A greater proportion of participants reported experiencing at least 1 minor respiratory and/or systemic adverse event after immunization during the at-risk period compared with the non–at-risk period (77% vs 54%, respectively). During the first week after LAIV, 13 of 168 (8%) children reported some wheezing, with the vast majority, 9 of 13 (69%), on the day of vaccination. CONCLUSIONS: There was no increased risk of respiratory deterioration or all-cause hospitalization associated with LAIV in our study population. LAIV seems well tolerated in children and adolescents with CF.

Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis

“…Detailed results of the detection of influenza viruses are published elsewhere. 18 Results were not stratified by influenza type given the small number of subjects.…”

Relationship Between Cannabis Use and Erectile Dysfunction: A Systematic Review and Meta-Analysis

“…In case of publication bias ( p < .10), the trim and fill-analysis (Duval & Tweedie, 2000) was applied for overcoming this bias. Finally, the fail-safe number (i.e., the number of studies for nullifying a significant result) (Boikos et al, 2014) was reported.…”

2014 year in review: Cystic fibrosis

“…Use of immunizations to help prevent or limit the severity of infections is a critical component of CF care, and was the subject of several studies in the past year. Use of the intranasal live attenuated influenza virus vaccine in 168 children with CF showed no difference in respiratory deterioration or all cause hospitalizations, despite a mild increase in wheezing, demonstrating the tolerability of this form of the vaccine . Patients with CF who received the conjugated pneumococcal vaccine had protective antibodies to all serotypes, whereas only 21% of those receiving the unconjugated vaccine had protection to the same seven serotypes, suggesting that conjugated vaccine may be adequate in this population .…”